JUR-003 in Adult Patients With Metastatic Prostate Cancer

JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.

Trial Details

NCT ID
NCT07824349
Phase
PHASE1
Sponsor
Juri Biosciences, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • JUR-003
Locations (sample)
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Lake Success, New York, United States|40.77066,-73.71763
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Must be ≥18 years of age at the time the informed consent form (ICF) is signed.
  • Has a histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Has either of the following:
  • Measurable disease per RECIST v1.1 (with PCWG3 modifications)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →